Is GSK (LSE:GSK) Undervalued Following Jideytro Approval?

The latest move in GSK (LSE:GSK) stock interest is tied to the early US FDA approval of Jideytro for ROS1 positive non small cell lung cancer, which expands the company’s oncology footprint.

See our latest analysis for GSK.

Despite the Jideytro approval and a series of recent product updates in vaccines and oncology, GSK’s share price has drifted lower over the past quarter. However, its 1 year total shareholder return of 42.21% and 5 year total shareholder return of 65.00% still point to solid long run gains.

If this kind of sector specific catalyst interests you, it can be helpful to scan a wider set of healthcare focused opportunities through the Simply Wall St screener for 6 healthcare AI stocks

GSK’s share price has cooled in recent weeks even as Jideytro and other products expand its oncology and vaccines line up. This leaves a wide gap between the current £19.06 price and several fair value estimates. How does that spread stack up?

Most Popular Narrative: 9.9% Undervalued

GSK’s most followed narrative puts fair value at £21.14, above the last close of £19.06. This helps explain why the recent share price softness is getting attention.

Strong volume growth in key high-margin areas like oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables) demonstrates GSK's ability to capture premium pricing and leverage long-term trends toward innovative, biologic, and personalized therapies, positively impacting future earnings and supporting margin expansion as these portfolios scale.

Read the complete narrative.

Want to see what sits underneath that oncology and immunology story? The fair value hinges on measured revenue growth, firmer margins, and a higher future earnings multiple. Curious which assumptions really move the £21.14 figure? The full narrative lays out the numbers and how they fit together.

Result: Fair Value of £21.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, GSK still faces overhangs from patent expiries and ongoing Zantac related legal settlements, which could affect future earnings and challenge the current valuation story.

Find out about the key risks to this GSK narrative.

Next Steps

Given the mix of optimism and concern around GSK, you may want to review the full set of data and sentiment yourself and decide where you stand by weighing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond GSK?

If GSK has sharpened your focus on quality and pricing power, do not stop there. Broaden your watchlist with other focused stock ideas that fit your style.

• Target reliable income streams by checking out companies in the 5 dividend fortresses that may suit a long term, yield focused portfolio.
• Spot opportunities that the market may be overlooking with the screener containing 10 high quality undiscovered gems, before wider attention catches up.
• Prioritise resilience by reviewing stocks in the 8 resilient stocks with low risk scores, so you are not caught off guard when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com